Compound: Tasimelteon
SMILES: O=C(NC[C@H]1[C@H](c2c3c(OCC3)ccc2)C1)CC
InChIKey: PTOIAAWZLUQTIO-GXFFZTMASA-N
Synonyms: Tasimelteon, 609799-22-6, Hetlioz, VEC-162, BMS-214778, VEC 162, HETLIOZ LQ, tasimelteonum, BMS 214778, BMS-214,778, SHS4PU80D9, BMS214778, CHEBI:79042, N-{[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamide, DTXSID70209826, N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl]propanamide, N-((2-(2,3-dihydro-4-benzofuranyl)cyclopropyl)methyl)propanamide, N-(((1R,2R)-2-(2,3-Dihydro-1-benzofuran-4-yl)cyclopropyl)methyl)propanamide, N-([(1r,2r)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl)propanamide, RefChem:57589, DTXCID20132317, N05CH03, MFCD09033789, N-(((1R,2R)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl)methyl)propionamide, Propanamide, N-(((1R,2R)-2-(2,3-dihydro-4-benzofuranyl)cyclopropyl)methyl)-, Tasimelteon [USAN], Tasimelteon [USAN:INN], UNII-SHS4PU80D9, BMS-214778;VEC-162, Hetlioz (TN), Tasimelteon (Standard), Tasimelteon Impurity 1, TASIMELTEON [MI], TASIMELTEON [INN], Tasimelteon (USAN/INN), TASIMELTEON [VANDF], TASIMELTEON [MART.], TASIMELTEON [WHO-DD], GTPL7393, orb1304147, SCHEMBL3505912, CHEMBL2103822, SCHEMBL29351713, Tasimelteon, >=98% (HPLC), TASIMELTEON [ORANGE BOOK], GLXC-07665, HMS3885L17, EX-A2729, BDBM50621041, EBC-26299, HY-14803R, s4281, AKOS025149360, N-[[(1R,2R)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl]methyl]propanamide, AC-6143, CCG-266915, CS-5512, DB09071, NCGC00522560-01, AS-35291, HY-14803, NS00034514, T3813, D09388, EN300-20605494, Q7687250, BRD-K62971431-001-01-9, (trans)-N-[[2-(2,3-dihydrobenzofuran-4-yl) cyclopropyl]methyl]propanamide, (trans)-N-[[2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl]methyl]propanamide, (-)-(trans)-N-[[2-(2,3-Dihydrobenzofuran-4-yl)cycloprop-1-yl] methyl]propanamide
Theoretical properties:
molecular_formula: C15H19NO2
molecular_weight: 245.32 g/mol
exact_mass: 245.141578849 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 2
rotatable_bond_count: 4
heavy_atom_count: 18
topological_polar_surface_area: 38.3 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
boiling_point: 442.553°C
Descriptions:
pubchem: Tasimelteon is a member of the class of 1-benzofurans that is propionamide in which one of the amide hydrogens is replaced by a [(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl group. A melatonin receptor agonist used for the treatment of non-24-hour sleep-wake disorder. It has a role as a melatonin receptor agonist. It is a monocarboxylic acid amide, a member of 1-benzofurans and a member of cyclopropanes. It is functionally related to a propionamide.
chebi: A member of the class of 1-benzofurans that is propionamide in which one of the amide hydrogens is replaced by a [(1<i>R</i>,2<i>R</i>)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl group. A melatonin receptor agonist used for the treatment of non-24-hour sleep-wake disorder.
chembl: TASIMELTEON is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Tasimelteon, sold under the brand name Hetlioz, is a medication approved by the U.S. Food and Drug Administration (FDA) in January 2014, for the treatment of non-24-hour sleep–wake disorder (also called non-24, N24 and N24HSWD). In June 2014, the European Medicines Agency (EMA) accepted an EU filing application for tasimelteon and in July 2015, the drug was approved in the European Union for the treatment of non-24-hour sleep-wake rhythm disorder in totally blind adults, but not in the case of non-24 in sighted people.
The most common side effects include headache, somnolence, nausea (feeling sick) and dizziness.